← Human Trials & Peer-Reviewed Studies
The influence of orlistat, metformin and diet on serum levels of insulin-like growth factor-1 in obeses women with and without insulin resistance
Plain-language guide to PMID 30683825 (2018): parallel-group randomized controlled trial study of IGF-1 LR3, insulin resistance, prediabetes & type 2 diabetes.
Key Facts
- PMID
- 30683825
- Journal
- Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
- Year
- 2018
- Study type
- Randomized Controlled Trial
- Authors
- Kujawska-Luczak M et al. (9 authors)
- DOI
- 10.26402/jpp.2018.5.08
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at IGF-1 LR3 in the context of insulin resistance, prediabetes & type 2 diabetes.
The aim of the study was to compare the influence of orlistat (IO), metformin (IM), or calorie-restricted diet (LC) on IGF-1, with special respect to insulin-resistance status.
Why It Was Studied
Before and after the intervention anthropometric parameters, serum lipid profile, serum concentrations of alanine aminotransferase, aspartate aminotransferase, insulin, glucose, IGF-1, HOMA-IR (homeostatic model assessment), and visceral adiposity index (VAI), and their changes were registered.
Who Took Part
PubMed indexes the participants as adults, women only.
How the Study Was Run
The researchers set it up as a randomized and parallel-group study.
Because people in this IGF-1 LR3 study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
The IGF-1 LR3 group and the comparison group ran side by side rather than switching.
What Was Measured
Before and after the intervention anthropometric parameters, serum lipid profile, serum concentrations of alanine aminotransferase, aspartate aminotransferase, insulin, glucose, IGF-1, HOMA-IR (homeostatic model assessment), and visceral adiposity index (VAI), and their changes were registered.
PubMed files the paper under topics including Anti-Obesity Agents, Caloric Restriction, Diet, Hypoglycemic Agents, Insulin Resistance, Insulin-Like Growth Factor I and Intra-Abdominal Fat.
What This Means in Plain Language
The paper is a randomized and parallel-group study of IGF-1 LR3 in people with insulin resistance, prediabetes & type 2 diabetes.
The publication is from 2018 (Journal of physiology and pharmacology : an official journal of the Polish Physiological Society), a journal based in Poland.
More context: the IGF-1 LR3 compound page, Insulin resistance, prediabetes & type 2 diabetes research.
Our Notes on the Compound
IGF-1 LR3: A modified IGF-1 analog that escapes binding proteins, so it stays active ≥24 h.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.